Fusion oncoproteins drive paediatric cancers but are challenging to target due to their intrinsic disorder and lack of druggable pockets. Here, authors present FusOn-pLM, trained on FusOn-DB, which uses dynamic masking to outperform baselines in fusion-specific tasks and predict drug-resistant mutations, advancing therapeutic design.
- Sophia Vincoff
- Shrey Goel
- Pranam Chatterjee
